BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29316213)

  • 1. Comparative effects of valsartan plus either cilnidipine or hydrochlorothiazide on home morning blood pressure surge evaluated by information and communication technology-based nocturnal home blood pressure monitoring.
    Fujiwara T; Tomitani N; Kanegae H; Kario K
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):159-167. PubMed ID: 29316213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of valsartan plus cilnidipine or hydrochlorothiazide on nocturnal home blood pressure.
    Fujiwara T; Hoshide S; Tomitani N; Kanegae H; Kario K
    J Clin Hypertens (Greenwich); 2021 Mar; 23(3):687-691. PubMed ID: 33497537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial.
    Lacourcière Y; Poirier L; Hebert D; Assouline L; Stolt P; Rehel B; Khder Y
    Clin Ther; 2005 Jul; 27(7):1013-21. PubMed ID: 16154480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension.
    Fujiwara T; Hoshide S; Yano Y; Kanegae H; Kario K
    J Clin Hypertens (Greenwich); 2017 Dec; 19(12):1319-1326. PubMed ID: 29106031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.
    Lacourcière Y; Crikelair N; Glazer RD; Yen J; Calhoun DA
    J Hum Hypertens; 2011 Oct; 25(10):615-22. PubMed ID: 21248785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
    Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
    Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
    Everett BM; Glynn RJ; Danielson E; Ridker PM;
    Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
    Eguchi K; Kario K; Hoshide Y; Hoshide S; Ishikawa J; Morinari M; Ishikawa S; Shimada K
    Am J Hypertens; 2004 Feb; 17(2):112-7. PubMed ID: 14751651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.
    Kario K; Ando S; Kido H; Nariyama J; Takiuchi S; Yagi T; Shimizu T; Eguchi K; Ohno M; Kinoshita O; Yamada T
    J Clin Hypertens (Greenwich); 2013 Feb; 15(2):133-42. PubMed ID: 23339732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial.
    Na SH; Lee HY; Hong Baek S; Jeon HK; Kang JH; Kim YN; Park CG; Ryu JK; Rhee MY; Kim MH; Hong TJ; Choi DJ; Cho SW; Cha DH; Jeon ES; Kim JJ; Shin JH; Park SH; Lee SH; John SH; Shin ES; Kim NH; Lee SY; Kwan J; Jeong MH; Kim SW; Jeong JO; Kim DW; Lee NH; Park WJ; Ahn JC; Won KH; Uk Lee S; Cho JH; Kim SK; Ahn T; Hong S; Yoo SY; Kim SY; Kim BS; Juhn JH; Kim SY; Lee YJ; Oh BH
    Clin Ther; 2015 Aug; 37(8):1726-39. PubMed ID: 26164786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide.
    Girerd X; Denolle T; Yau C; Fiquet B; Brunel P; Moulin B; Herpin D
    Blood Press Suppl; 2004 Dec; 2():18-24. PubMed ID: 15631279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
    Oigman W; Gomes MA; Pereira-Barretto AC; Póvoa R; Kohlmann O; Rocha JC; Nobre F
    Clin Ther; 2013 May; 35(5):702-10. PubMed ID: 23623755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of combination therapy using high- or low-dose hydrochlorothiazide with valsartan or other Angiotensin-receptor blockers.
    Fuenfstueck R; Hempel RD; Ansari A; Weidinger G; Klebs S
    Adv Ther; 2005; 22(3):263-77. PubMed ID: 16236687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.